Technical Analysis for XGN - Exagen Inc.

Grade Last Price % Change Price Change
F 1.59 1.92% 0.03
XGN closed up 1.92 percent on Thursday, March 28, 2024, on 67 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 1.92%
Oversold Stochastic Weakness 1.92%
Calm After Storm Range Contraction 3.25%
Inside Day Range Contraction 3.25%
Wide Bands Range Expansion 3.25%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 20 hours ago
Rose Above 10 DMA about 20 hours ago
10 DMA Resistance about 21 hours ago
Up 5% about 21 hours ago
Up 3% about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Exagen Inc. Description

Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Disease Immunology Autoimmune Disease Bone Disorders Autoimmunity Rheumatoid Arthritis Blood Test Lupus Rheumatology Glutamate Fibromyalgia Systemic Lupus Erythematosus Erythema Methotrexate Scleroderma Sjögren's Syndrome

Is XGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.9232
52 Week Low 1.33
Average Volume 38,859
200-Day Moving Average 2.13
50-Day Moving Average 1.93
20-Day Moving Average 1.74
10-Day Moving Average 1.59
Average True Range 0.18
RSI (14) 42.20
ADX 16.84
+DI 18.56
-DI 22.11
Chandelier Exit (Long, 3 ATRs) 1.76
Chandelier Exit (Short, 3 ATRs) 1.95
Upper Bollinger Bands 2.08
Lower Bollinger Band 1.40
Percent B (%b) 0.28
BandWidth 39.37
MACD Line -0.12
MACD Signal Line -0.11
MACD Histogram -0.0131
Fundamentals Value
Market Cap 27.1 Million
Num Shares 17 Million
EPS -1.86
Price-to-Earnings (P/E) Ratio -0.85
Price-to-Sales 0.68
Price-to-Book 1.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.77
Resistance 3 (R3) 1.77 1.71 1.74
Resistance 2 (R2) 1.71 1.66 1.71 1.73
Resistance 1 (R1) 1.65 1.63 1.68 1.65 1.72
Pivot Point 1.59 1.59 1.60 1.59 1.59
Support 1 (S1) 1.53 1.54 1.56 1.53 1.46
Support 2 (S2) 1.47 1.52 1.47 1.45
Support 3 (S3) 1.41 1.47 1.44
Support 4 (S4) 1.41